Senseonics (NYSE:SENS) announced today that it received CE mark for the next-generation Eversense E3 CGM system. Germantown, Maryland-based Senseonics offered its previous-generation continuous glucose monitor (CGM) with a 90-day wear time. Its next-generation Eversense E3 can be used for up to six months (180 days). Europe already had a 180-day Senseonics CGM system available (Eversense XL), […]
Patient Monitoring
Data backs Pear Therapeutics digital therapeutic for opioid use disorder
Pear Therapeutics (Nasdaq:PEAR) today shared real-world data highlighting low costs with its reSET-O prescription digital therapeutic (PDT). Boston-based Pear Therapeutics’ reSET-O represents the only FDA-authorized PDT for the treatment of opioid use disorder (OUD). Get the full story at our sister site, Drug Delivery Business News.
Dexcom quadruples number of shares
Dexcom (Nasdaq:DXCM) recently filed a restated certificate of incorporation to effect a four-for-one forward stock split. Shares of DXCM were down 0.9% at $293.85 per share at market close on Friday, June 10. Following the stock split, shares moved down 75.33% to $72.50 before the market opened this morning. At market open, shares were down 3.4% […]
Data supports Beta Bionics’ iLet bionic pancreas
Beta Bionics announced today that a trial of its iLet bionic pancreas met key endpoints, including reduced HbA1c. Dr. Roy W. Beck and clinical investigators presented the results of the multi-center, randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. According to a news release, […]
Medicalgorithmics wins FDA nod for wearable ECG
Medicalgorithmics announced today that the FDA approved its Qpatch wearable device for electrocardiogram (ECG) readings. Warsaw, Poland–based Medicalgorithmics designed the state-of-the-art, wearable device to measure individual ECG signals and obtain accurate cardiac arrhythmia diagnoses across up to 15 days of monitoring sessions. According to a news release, Medicalgorithmics’ Qpatch has been selected for a clinical […]
The biggest stories from the American Diabetes Association (ADA) 2022 Scientific Sessions
For the 82nd time, the American Diabetes Association (ADA) Scientific Sessions convened to highlight all the innovations within the diabetes technology space. Major players like Dexcom, Medtronic, Abbott and more continue to plug along, while companies like Bigfoot Biomedical, One Drop and others shared data backing the technology that they bring to the table. The […]
Dexcom CEO expects ‘science boom’ with CGM, automated insulin delivery
With the G7 nearing FDA clearance, Dexcom leadership foresees major innovations for integrated automated insulin delivery down the line. Kevin Sayer began thinking about automated insulin delivery all the way back in 1994 when he was working at MiniMed. Nearly 30 years later, as CEO of Dexcom (Nasdaq:DXCM), that space continues to pique his interest. In the […]
Tandem reports positive data for t:slim X2 insulin pump with Control-IQ technology
Tandem Diabetes Care (Nasdaq:TNDM) announced today that real-world data supports its t:slim X2 insulin pump with Control-IQ technology. Data from the ongoing real-world Control-IQ observational (CLIO) study demonstrating immediate and sustained benefits in a diverse cohort of participants was presented at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. Get the full story […]
One Drop studies show improved attitudes toward CGM, diabetes management platform
One Drop announced positive data from multiple studies evaluating the opinions of people with diabetes on continuous glucose monitoring. New York-based One Drop presented new research about attitudes and adoption of continuous glucose monitors (CGMs) among people with type 2 diabetes at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. Get the full […]
Bigfoot Biomedical’s Bigfoot Unity demonstrates strong glycemic control in Type 2 diabetes
Bigfoot Biomedical announced data supporting the use of its Bigfoot Unity system for improving glycemic control in those with diabetes. Data from a real-world retrospective analysis suggests that, for those on multiple daily injections (MDI) of insulin, Bigfoot Unity has the potential to provide rapid and durable glycemic control improvements. Milpitas, California–based Bigfoot presented the real-world […]
Late-breaking data supports Abbott FreeStyle Libre 3 in 14-day glucose monitoring
Abbott (NYSE:ABT) announced data demonstrating the accuracy of its next-generation FreeStyle Libre 3 continuous glucose monitor (CGM). The latest version of the company’s FreeStyle Libre platform — designed as the smallest and thinnest CGM sensor in the world at the size of just two stacked U.S. pennies — picked up FDA clearance for people with diabetes aged […]